{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:52:40Z","timestamp":1790833960826,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,12,20]],"date-time":"2014-12-20T00:00:00Z","timestamp":1419033600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40273-014-0245-8","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T15:38:57Z","timestamp":1419003537000},"page":"381-393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX\u00ae) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective"],"prefix":"10.1007","volume":"33","author":[{"given":"Rizwan","family":"Hamid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Loveman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Millen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Globe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Corbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Colayco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Stanisic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Gultyaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,20]]},"reference":[{"key":"245_CR1","volume-title":"Clinical guideline\u00a0148: urinary incontinence in neurological disease","author":"National Institute for Health and Care Excellence","year":"2012","unstructured":"National Institute for Health and Care Excellence. Clinical guideline\u00a0148: urinary incontinence in neurological disease. London: NICE; 2012."},{"key":"245_CR2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/nau.20870","volume":"29","author":"P Abrams","year":"2010","unstructured":"Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29:213\u201340.","journal-title":"Neurourol Urodyn."},{"key":"245_CR3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-7525-11-13","volume":"11","author":"CI Tapia","year":"2013","unstructured":"Tapia CI, Khalaf K, Berenson K, Globe D, Chancellor M, Carr LK. Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review. Health Qual Life Outcomes. 2013;11:13.","journal-title":"Health Qual Life Outcomes."},{"key":"245_CR4","volume-title":"NICE pathways: treatment to improve bladder storage in people with neurological disease","author":"National Institute for Health and Care Excellence","year":"2013","unstructured":"National Institute for Health and Care Excellence. NICE pathways: treatment to improve bladder storage in people with neurological disease. London: NICE; 2013."},{"key":"245_CR5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1368-5031.2005.00617.x","volume":"59","author":"F Haab","year":"2005","unstructured":"Haab F, Castro-Diaz D. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract. 2005;59:931\u20137.","journal-title":"Int J Clin Pract."},{"key":"245_CR6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/nau.21003","volume":"30","author":"A Manack","year":"2010","unstructured":"Manack A, Motsko SP, Haag-Molkenteller C, Dmochowski RR, Goehring EL Jr, Nguyen-Khoa BA, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn. 2010;30:395\u2013401.","journal-title":"Neurourol Urodyn."},{"key":"245_CR7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1592\/phco.20.5.470.35064","volume":"20","author":"M Lawrence","year":"2000","unstructured":"Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy. 2000;20:470\u20135.","journal-title":"Pharmacotherapy."},{"key":"245_CR8","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1464-410X.2011.10509.x","volume":"109","author":"PM Gurung","year":"2012","unstructured":"Gurung PM, Attar KH, Abdul-Rahman A, Morris T, Hamid R, Shah PJ. Long-term outcomes of augmentation ileocystoplasty in patients with spinal cord injury: a minimum of 10\u00a0years of follow-up. BJU Int. 2012;109:1236\u201342.","journal-title":"BJU Int."},{"key":"245_CR9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/sj.sc.3101033","volume":"38","author":"EJ Chartier-Kastler","year":"2000","unstructured":"Chartier-Kastler EJ, Mongiat-Artus P, Bitker MO, Chancellor MB, Richard F, Denys P. Long-term results of augmentation cystoplasty in spinal cord injury patients. Spinal Cord. 2000;38:490\u20134.","journal-title":"Spinal Cord."},{"key":"245_CR10","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60:742\u201350.","journal-title":"Eur Urol."},{"key":"245_CR11","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","volume":"187","author":"D Ginsberg","year":"2012","unstructured":"Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase\u00a03 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131\u20139.","journal-title":"J Urol."},{"key":"245_CR12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s12325-013-0054-z","volume":"30","author":"D Ginsberg","year":"2013","unstructured":"Ginsberg D, Cruz F, Herschorn S, Gousse A, Keppenne V, Aliotta P, et al. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor activity regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther. 2013;30:819\u201333.","journal-title":"Adv Ther."},{"key":"245_CR13","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.clinthera.2013.02.020","volume":"35","author":"JJ Carlson","year":"2013","unstructured":"Carlson JJ, Hansen RN, Dmochowski RR, Globe DR, Colayco DC, Sullivan SD. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States. Clin Ther. 2013;35:414\u201324.","journal-title":"Clin Ther."},{"key":"245_CR14","unstructured":"All Wales Medicines Strategy Group Secretariat assessment report. Botulinum toxin type A (Botox) (50\u00a0units, 100\u00a0units, 200\u00a0units powder for solution for injection): reference number 1429 (full submission). Cardiff: All Wales Medicines Strategy Group; 2013."},{"key":"245_CR15","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","volume":"13","author":"FA Sonnenberg","year":"1993","unstructured":"Sonnenberg FA, Beck JR. Markov models in medical decision making a practical guide. Med Decision Making. 1993;13:322\u201338.","journal-title":"Med Decision Making."},{"key":"245_CR16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2008.08.048","volume":"55","author":"A Giannantoni","year":"2009","unstructured":"Giannantoni A, Mearini E, Del Zingaro M, Porena M. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol. 2009;55:705\u201311.","journal-title":"Eur Urol."},{"key":"245_CR17","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.juro.2010.12.002","volume":"185","author":"S Khan","year":"2011","unstructured":"Khan S, Game X, Kalsi V, Gonzales G, Panicker J, Elneil S, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185:1344\u20139.","journal-title":"J Urol."},{"key":"245_CR18","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0090-4295(98)00220-9","volume":"52","author":"S Herschorn","year":"1998","unstructured":"Herschorn S, Hewitt RJ. Patient perspective of long-term outcome of augmentation cystoplasty for neurogenic bladder. Urology. 1998;52:672\u20138.","journal-title":"Urology."},{"key":"245_CR19","volume-title":"Guide to the methods of technology appraisal 2013\u2014NICE guidance","author":"National Institute for Health and Care Excellence","year":"2013","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013\u2014NICE guidance. London: NICE; 2013."},{"key":"245_CR20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.apmr.2007.02.009","volume":"88","author":"B Schurch","year":"2007","unstructured":"Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron R. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil. 2007;88:646\u201352.","journal-title":"Arch Phys Med Rehabil."},{"key":"245_CR21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12955-014-0147-7","volume":"12","author":"J Cuervo","year":"2014","unstructured":"Cuervo J, Castejon N, Khalaf KM, Waweru C, Globe D, Patrick DL. Development of the Incontinence Utility Index: estimating population-based utilities associated with urinary problems from the Incontinence Quality of Life questionnaire and Neurogenic Module. Health Qual Life Outcomes. 2014;12:147.","journal-title":"Health Qual Life Outcomes."},{"key":"245_CR22","unstructured":"British Medical Association. British national formulary: No 65. British Medical Association and Royal Pharmaceutical Society of Great Britain; 2013."},{"key":"245_CR23","unstructured":"Department of Health. NHS reference costs 2011\u20132012. London: Department of Health; 2013."},{"key":"245_CR24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","volume":"15","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health. 2012;15:835\u201342.","journal-title":"Value Health."},{"key":"245_CR25","unstructured":"Scottish Medicines Consortium. Detailed advice document: botulinum toxin type A 50, 100, 200 Allergan units\/vial (Botox\u00ae): SMC # 916\/13. Glasgow: Scottish Medicines Consortium; 2013."},{"key":"245_CR26","unstructured":"All Wales Medicines Strategy Group Secretariat assessment report. Botulinum toxin type A (Botox) (50\u00a0units, 100\u00a0units, 200\u00a0units powder for solution for injection): reference number 1429 (Advice). Cardiff: All Wales Medicines Strategy Group; 2013."},{"key":"245_CR27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2005.11.006","volume":"49","author":"V Kalsi","year":"2006","unstructured":"Kalsi V, Popat RB, Apostolidis A, Kavia R, Odeyemi IA, Dakin HA, et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol. 2006;49:519\u201327.","journal-title":"Eur Urol."},{"key":"245_CR28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3111\/13696990903543085","volume":"13","author":"H Naci","year":"2010","unstructured":"Naci H, Fleurence R, Birt J, Duhig A. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. J Med Econ. 2010;13:78\u201389.","journal-title":"J Med Econ."},{"key":"245_CR29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1682\/JRRD.2004.08.0100","volume":"42","author":"MP Dijkers","year":"2005","unstructured":"Dijkers MP. Quality of life of individuals with spinal cord injury: a review of conceptualization, measurement, and research findings. J Rehabil Res Dev. 2005;42:87\u2013110.","journal-title":"J Rehabil Res Dev."},{"key":"245_CR30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jval.2010.08.006","volume":"14","author":"S Arlandis","year":"2011","unstructured":"Arlandis S, Castro D, Errando C, Fernandez E, Jimenez M, Gonzalez P, et al. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin A or continued medical management in refractory overactive bladder. Value Health. 2011;14:219\u201328.","journal-title":"Value Health."},{"key":"245_CR31","doi-asserted-by":"crossref","unstructured":"Lichstein JC, Biddle AK, Lavelle J. Cost-utility analysis of sacral nerve stimulation and botulinum-A for the treatment of urinary urge incontinence in women 65 and older. UroToday Int J. 2008;1(1 Suppl):9.","DOI":"10.3834\/uij.1939-4810.2008.06.14"},{"key":"245_CR32","first-page":"41","volume":"14","author":"SE Schultz","year":"2003","unstructured":"Schultz SE, Kopec JA. Impact of chronic conditions. Health Rep. 2003;14:41\u201353.","journal-title":"Health Rep."},{"key":"245_CR33","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.juro.2009.08.031","volume":"182","author":"NY Siddiqui","year":"2009","unstructured":"Siddiqui NY, Amundsen CL, Visco AG, Myers ER, Wu JM. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol. 2009;182:2799\u2013804.","journal-title":"J Urol."},{"key":"245_CR34","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.juro.2009.01.037","volume":"181","author":"JM Wu","year":"2009","unstructured":"Wu JM, Siddiqui NY, Amundsen CL, Myers ER, Havrilesky LJ, Visco AG. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. J Urol. 2009;181:2181\u20136.","journal-title":"J Urol."},{"key":"245_CR35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11136-010-9590-z","volume":"19","author":"W Hollingworth","year":"2010","unstructured":"Hollingworth W, Campbell JD, Kowalski J, Ravelo A, Girod I, Briggs A, et al. Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. Qual Life Res. 2010;19:323\u201331.","journal-title":"Qual Life Res."},{"key":"245_CR36","unstructured":"Clinical key: urinary incontinence. Elsevier; http:\/\/www.clinicalkey.com\/topics\/urology\/urinary-incontinence.html . Accessed 27 Jan 2014."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-014-0245-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-014-0245-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-014-0245-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T16:37:37Z","timestamp":1566146257000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-014-0245-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,20]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1007\/s40273-014-0245-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,20]]}}}